Lofexidine

Generic Name: Lofexidine

Brand Names: Lucemyra

Drug Type: Small Molecule

Chemical Formula: C_₁₁H_₁₂Cl_₂N_₂O

CAS Number: 31036-80-3

Unique Ingredient Identifier: UI82K0T627

Background: Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hypertension than clonidine. Lofexidine was...

Indication: Lofexidine is indicated for mitigation of symptoms associated with acute withdrawal from opioids and for facilitation of the completion of opioid discontinuation treatment. It is the first non-opioid medication for the symptomatic management of opioid discontinuation.
...

Associated Conditions: Abrupt opioid withdrawal

Associated Therapies: -

Clinical Trials

Lofexidine for Inpatient Opiate Detox in Singapore

Phase 4

Completed

Conditions: Opiate Dependent Patients Who Are Undergoing Inpatient Detoxification in Singapore

Interventions: Drug: Lofexidine
Drug: Diazepam
Drug: Placebo for Diazepam
Drug: Placebo for Lofexidine

First Posted Date: 2012-08-30

Last Posted Date: 2015-08-28

Lead Sponsor: Institute of Mental Health, Singapore

Target Recruit Count: 112

Registration Number: NCT01675648

Locations: 🇸🇬
National Addictions Management Service, Institute of Mental Health, Singapore, Singapore, Singapore

Interactions Between Intravenous (IV) Cocaine and Lofexidine

Phase 1

Terminated

Conditions: Cocaine Related Disorders

Interventions: Drug: Placebo
Drug: Lofexidine

First Posted Date: 2010-06-23

Last Posted Date: 2017-01-11

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 16

Registration Number: NCT01148992

Locations: 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸
California Pacific Medical Center Research Institute, San Francisco, California, United States

Combined Pharmacotherapy for Cannabis Dependency

Phase 2

Completed

Conditions: Cannabis Dependence
Marijuana Dependence

Interventions: Drug: Placebo
Drug: Dronabinol
Drug: Lofexidine

First Posted Date: 2009-11-25

Last Posted Date: 2019-04-24

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 156

Registration Number: NCT01020019

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Effect of Lofexidine and Oral THC on Marijuana Withdrawal and Relapse

Phase 2

Completed

Conditions: Marijuana Dependence

Interventions: Drug: Lofexidine
Drug: dronabinol
Drug: Marijuana

First Posted Date: 2006-09-08

Last Posted Date: 2013-02-05

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 8

Registration Number: NCT00373503

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Lofexidine for Inpatient Opiate Detox

Phase 3

Completed

Conditions: Opiate Addiction

Interventions: Drug: Placebo
Drug: Lofexidine

First Posted Date: 2005-10-10

Last Posted Date: 2009-03-20

Lead Sponsor: US Department of Veterans Affairs

Target Recruit Count: 264

Registration Number: NCT00235729

Locations: 🇺🇸
CNS, Cerritos, Cerritos, California, United States
🇺🇸
CNS Psychiatric Institute of Washington, Washington, District of Columbia, United States
🇺🇸
Atlanta Center for Medical Research, Atlanta, Georgia, United States

and more 13 locations

Effectiveness of Naltrexone and Lofexidine in Treating Detoxified Heroin Addicts - 1

Phase 1

Completed

Conditions: Heroin Dependence

First Posted Date: 2005-09-22

Last Posted Date: 2017-01-12

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Registration Number: NCT00218530

Locations: 🇺🇸
Substance Abuse Treatment Unit, New Haven, Connecticut, United States

Effectiveness of Lofexidine to Prevent Stress-Related Opiate Relapse During Naltrexone Treatment - 1

Phase 2

Completed

Conditions: Opioid-Related Disorders

Interventions: Drug: Placebo
Drug: Lofexidine

First Posted Date: 2005-09-02

Last Posted Date: 2015-07-30

Lead Sponsor: Yale University

Target Recruit Count: 86

Registration Number: NCT00142909

Locations: 🇺🇸
Yale University, Psychiatry, New Haven, Connecticut, United States

Lofexidine for Opiate Withdrawal - 1

Phase 3

Completed

Conditions: Opioid-Related Disorders

First Posted Date: 2002-04-08

Last Posted Date: 2017-01-12

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 66

Registration Number: NCT00032942

Locations: 🇺🇸
Philadelphia Veterans Medical Center, Philadelphia, Pennsylvania, United States
🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸
Columbia University, New York, New York, United States

Evaluation of Lofexidine for Treatment of Opiate Withdrawal - 10

Phase 1

Completed

Conditions: Opioid-Related Disorders

First Posted Date: 1999-09-21

Last Posted Date: 2017-01-12

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Registration Number: NCT00000345

Locations: 🇺🇸
Friends Research Institute, Los Angeles, California, United States

Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7

Phase 1

Completed

Conditions: Opioid-Related Disorders
Substance-Related Disorders

First Posted Date: 1999-09-21

Last Posted Date: 2017-01-12

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Registration Number: NCT00000358

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy